M

17 March 2008

M's Science Corp has granted rights to fellow Japanese drugmaker Eisai under an option agreement for SA4503, a novel sigma agonist which is being developed by M's Science in Europe for the treatment of depression and post-stroke therapy. Under the terms of the deal, M's Science will grant Eisai the following in exchange for a certain payment: the first review right for evaluating the results of the two Phase II studies of the compound currently ongoing in Europe for the above two indications and the first negotiation right regarding the development and marketing of the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Medicus Pharma

A clinical-stage biopharmaceutical company focused on advancing selected therapeutic assets through mid-stage clinical development. Medicus Pharma’s operating model centers on generating Phase II proof-of-concept data and partnering or licensing programs to larger pharmaceutical companies for late-stage development and commercialization.

| Headless Content Management with Blaze